- Home
- ASM vs FLGT Comparison
ASM vs FLGT Comparison
Compare ASM & FLGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASM
- FLGT
- Stock Information
- Founded
- ASM 1968
- FLGT 2011
- Country
- ASM Canada
- FLGT United States
- Employees
- ASM N/A
- FLGT N/A
- Industry
- ASM Metal Mining
- FLGT Medical Specialities
- Sector
- ASM Basic Materials
- FLGT Health Care
- Exchange
- ASM Nasdaq
- FLGT Nasdaq
- Market Cap
- ASM 612.8M
- FLGT 587.3M
- IPO Year
- ASM N/A
- FLGT 2016
- Fundamental
- Price
- ASM $3.91
- FLGT $21.26
- Analyst Decision
- ASM Strong Buy
- FLGT Buy
- Analyst Count
- ASM 3
- FLGT 3
- Target Price
- ASM $3.73
- FLGT $25.33
- AVG Volume (30 Days)
- ASM 5.0M
- FLGT 369.0K
- Earning Date
- ASM 08-13-2025
- FLGT 08-01-2025
- Dividend Yield
- ASM N/A
- FLGT N/A
- EPS Growth
- ASM 1940.36
- FLGT N/A
- EPS
- ASM 0.11
- FLGT N/A
- Revenue
- ASM $79,639,000.00
- FLGT $303,223,000.00
- Revenue This Year
- ASM $31.71
- FLGT $11.79
- Revenue Next Year
- ASM $28.15
- FLGT $10.45
- P/E Ratio
- ASM $39.76
- FLGT N/A
- Revenue Growth
- ASM 53.08
- FLGT 4.31
- 52 Week Low
- ASM $0.85
- FLGT $14.57
- 52 Week High
- ASM $4.41
- FLGT $23.99
- Technical
- Relative Strength Index (RSI)
- ASM 59.17
- FLGT 63.44
- Support Level
- ASM $3.67
- FLGT $19.59
- Resistance Level
- ASM $4.00
- FLGT $21.93
- Average True Range (ATR)
- ASM 0.22
- FLGT 0.84
- MACD
- ASM 0.04
- FLGT 0.34
- Stochastic Oscillator
- ASM 76.06
- FLGT 85.60
About ASM Avino Silver & Gold Mines Ltd. (Canada)
Avino Silver & Gold Mines Ltd is a mineral resource company. It is engaged in the exploration, extraction, and processing of silver, gold, and copper and the acquisition, exploration, and advancement of mineral properties. The company generates majority of its revenues through the sale of Copper produced from its mines. Its project portfolio includes Avino; San Gonzalo; Oxide Tailings; Bralorne Gold and others.
About FLGT Fulgent Genetics Inc.
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in laboratory services business and a therapeutic development business. The laboratory services business which generates key revenue includes, technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue; and Foreign.